Immune checkpoint inhibitors: current status.

Autor:	Palma Dos Reis AF; Serviço de Oncologia, Hospital Santo António dos Capuchos, Lisboa, Portugal palmareis@gmail.com.; Anatomia, Universidade Nova de Lisboa Faculdade de Ciências Médicas de Lisboa, Lisboa, Portugal., Hennig I; Clinical Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK., Wilcock A; Palliative Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Jazyk:	angličtina
Zdroj:	BMJ supportive & palliative care [BMJ Support Palliat Care] 2021 Jun 15. Date of Electronic Publication: 2021 Jun 15.
DOI:	10.1136/bmjspcare-2021-002954
Abstrakt:	The use of immune checkpoint inhibitors (ICIs) is growing rapidly in oncology and palliative care clinicians and other generalists will increasingly see patients who are receiving, or who have received ICI. For optimal care, it is important that clinicians have a basic understanding of the unique nature of ICI as anticancer treatments, including patterns of response, potential issues with concurrent corticosteroid use and the wide range of possible immune-related adverse effects (IrAEs). This paper, informed by a recent literature search, provides a succinct yet comprehensive overview of ICI, with a particular focus on IrAE, highlighting that some are potentially life-threatening and/or can develop a long time, sometimes years, after even a short course of an ICI. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu